CL2018003322A1 - Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128) - Google Patents

Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)

Info

Publication number
CL2018003322A1
CL2018003322A1 CL2018003322A CL2018003322A CL2018003322A1 CL 2018003322 A1 CL2018003322 A1 CL 2018003322A1 CL 2018003322 A CL2018003322 A CL 2018003322A CL 2018003322 A CL2018003322 A CL 2018003322A CL 2018003322 A1 CL2018003322 A1 CL 2018003322A1
Authority
CL
Chile
Prior art keywords
interleukin
inflammatory diseases
peptide inhibitors
divisional application
treat inflammatory
Prior art date
Application number
CL2018003322A
Other languages
Spanish (es)
Inventor
David Liu
Jie Zhang
Gregory Bourne
Xiaoli Cheng
Brian Troy Frederick
Dinesh V Patel
Ashok Bhandari
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of CL2018003322A1 publication Critical patent/CL2018003322A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA INHIBIDORES PEPTÍDICOS NOVEDOSOS DEL RECEPTOR DE INTERLEUCINA 23 Y COMPOSICIONES Y MÉTODOS RELACIONADOS PARA UTILIZAR ESTOS INHIBIDORES PEPTIDICOS PARA EL TRATAMIENTO O LA PREVENCIÓN DE DIVERSAS ENFERMEDADES Y TRASTORNOS, INCLUIDAS ENFERMEDADES INTESTINALES INFLAMATORIAS.THE PRESENT INVENTION PROVIDES NOVEDOUS PEPTIDE INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND RELATED COMPOSITIONS AND METHODS FOR USING THESE PEPTIDIC INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIFFERENT INFRASTRUCTURAL DISEASES, INCLUDING.

CL2018003322A 2015-07-15 2018-11-22 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128) CL2018003322A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20

Publications (1)

Publication Number Publication Date
CL2018003322A1 true CL2018003322A1 (en) 2019-01-18

Family

ID=57757647

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018000128A CL2018000128A1 (en) 2015-07-15 2018-01-15 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases
CL2018003322A CL2018003322A1 (en) 2015-07-15 2018-11-22 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)
CL2021000343A CL2021000343A1 (en) 2015-07-15 2021-02-09 Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018000128A CL2018000128A1 (en) 2015-07-15 2018-01-15 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021000343A CL2021000343A1 (en) 2015-07-15 2021-02-09 Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (2) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX2018000542A (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11472842B2 (en) 2015-12-30 2022-10-18 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11807674B2 (en) 2013-03-15 2023-11-07 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US11884748B2 (en) 2014-07-17 2024-01-30 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3143037B1 (en) 2014-05-16 2021-06-23 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
BR112017006826A2 (en) 2014-10-01 2017-12-12 Protagonist Therapeutics Inc new antagonist a4ss7 peptide monomers and dimers
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CN115925790A (en) 2016-03-23 2023-04-07 领导医疗有限公司 Methods for synthesizing alpha 4 beta 7 peptide antagonists
EP3570864A4 (en) * 2017-01-18 2020-12-30 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
JP2022540154A (en) 2019-07-10 2022-09-14 プロタゴニスト セラピューティクス， インコーポレイテッド Peptide inhibitors of the interleukin-23 receptor and their use for treating inflammatory diseases
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4090670A1 (en) 2020-01-15 2022-11-23 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
CA3226492A1 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Bicyclic peptide inhibitors of interleukin-23 receptor
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
MX2009008241A (en) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) * 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
US9624268B2 (en) * 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11807674B2 (en) 2013-03-15 2023-11-07 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US11884748B2 (en) 2014-07-17 2024-01-30 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11472842B2 (en) 2015-12-30 2022-10-18 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
BR112018000691A2 (en) 2018-09-18
JP2018522008A (en) 2018-08-09
KR20180030663A (en) 2018-03-23
EA035733B9 (en) 2021-01-14
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
SV2018005614A (en) 2018-05-22
DOP2018000010A (en) 2018-03-30
CR20180029A (en) 2018-06-05
PE20180571A1 (en) 2018-04-04
WO2017011820A2 (en) 2017-01-19
EA035733B1 (en) 2020-07-31
AU2016293619A1 (en) 2018-02-01
SG10201912066SA (en) 2020-02-27
HK1259149A1 (en) 2019-11-29
PH12018500086A1 (en) 2018-07-30
WO2017011820A3 (en) 2017-02-23
UA123772C2 (en) 2021-06-02
CN108348580B (en) 2022-05-10
HK1257747A1 (en) 2019-10-25
CL2021000343A1 (en) 2021-08-06
ECSP18002929A (en) 2018-03-31
IL256827A (en) 2018-03-29
CO2018000349A2 (en) 2018-07-10
CL2018000128A1 (en) 2018-06-15
NI201800008A (en) 2018-06-29
KR102513978B1 (en) 2023-03-27
JP6858174B2 (en) 2021-04-14
EA201890325A1 (en) 2018-06-29
CA2991984A1 (en) 2017-01-19
EP3341011A2 (en) 2018-07-04
MX2018000542A (en) 2018-06-27
CN108348580A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2018003322A1 (en) Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)
CY1124013T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
CY1125136T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
CY1122148T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
CY1123381T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
CY1122184T1 (en) COMPOSITIONS INCLUDING BACTERIAL STRAINS
CY1122344T1 (en) BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
CY1121473T1 (en) COMPOSITIONS INCLUDING BACTERIAL STRENGTHS
EA201891199A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
AR119389A1 (en) INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
BR112022000328A2 (en) Interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases
CL2018000317A1 (en) Use of anti-cd40 antibodies for the treatment of lupus nephritis
MX2021006977A (en) Anellosomes and methods of use.
CL2016002321A1 (en) Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders.
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
MA40642A (en) Novel peptide derivatives and uses thereof
NZ723269A (en) Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
DOP2017000136A (en) COMPOUNDS TO TREAT CANCER